Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly stock rose Thursday despite lighter-than-expected sales of its weight-loss and diabetes drugs Zepbound and Mounjaro.

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

Eli Lilly (NYSE: LLY) sells a broad variety of drugs across treatment areas, but one particular portfolio has driven growth in recent times -- and this is likely to continue. I'm talking about Lilly's ...

Shares of Eli Lilly & Co. were headed for their worst ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Patients who took popular weight loss drugs were 12 per cent less likely ... diabetes such as Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro could have significant effects on ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...